The Next 10 Years in Atrial Fibrillation

Predicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeffrey L Turner, Nassir Marrouche
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/55fab9d19d034ce39a86a21f63a95b72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55fab9d19d034ce39a86a21f63a95b72
record_format	dspace
spelling	oai:doaj.org-article:55fab9d19d034ce39a86a21f63a95b722021-12-04T16:01:09ZThe Next 10 Years in Atrial Fibrillation10.15420/usc.2018.21.21758-390X1758-3896https://doaj.org/article/55fab9d19d034ce39a86a21f63a95b722019-01-01T00:00:00Zhttps://www.uscjournal.com/articles/10-years-atrial-fibrillationhttps://doaj.org/toc/1758-3896https://doaj.org/toc/1758-390XPredicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far from perfect. Over the next decade we expect significant continued progress in AF management. However, if asked to forecast the future, we consider it wise to predict advancements in the nearer term. We believe there will be widespread expansion in digital health and mobile devices, altering the way we detect and monitor the arrhythmia. We expect substantial growth in advanced MRI to aid in early detection, evaluation, and possibly non-invasive treatment of AF substrate. We imagine there will be increasing focus on individual populations to identify at-risk groups and personalize early management. We also anticipate improvement in anticoagulation employment and left atrial appendage modification. Finally, recognizing the benefit of improvement in modifiable risk factors such as mandatory tobacco cessation and weight loss in obese patients, we predict that reimbursement will be dependent on successfully addressing modifiable risk. For now, several questions remain unanswered, and while no one can predict the next 10 years in AF, there is, without doubt, an abundance of opportunity.Jeffrey L TurnerNassir MarroucheRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENUS Cardiology Review , Vol 13, Iss 1, Pp 54-57 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Jeffrey L Turner Nassir Marrouche The Next 10 Years in Atrial Fibrillation
description	Predicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far from perfect. Over the next decade we expect significant continued progress in AF management. However, if asked to forecast the future, we consider it wise to predict advancements in the nearer term. We believe there will be widespread expansion in digital health and mobile devices, altering the way we detect and monitor the arrhythmia. We expect substantial growth in advanced MRI to aid in early detection, evaluation, and possibly non-invasive treatment of AF substrate. We imagine there will be increasing focus on individual populations to identify at-risk groups and personalize early management. We also anticipate improvement in anticoagulation employment and left atrial appendage modification. Finally, recognizing the benefit of improvement in modifiable risk factors such as mandatory tobacco cessation and weight loss in obese patients, we predict that reimbursement will be dependent on successfully addressing modifiable risk. For now, several questions remain unanswered, and while no one can predict the next 10 years in AF, there is, without doubt, an abundance of opportunity.
format	article
author	Jeffrey L Turner Nassir Marrouche
author_facet	Jeffrey L Turner Nassir Marrouche
author_sort	Jeffrey L Turner
title	The Next 10 Years in Atrial Fibrillation
title_short	The Next 10 Years in Atrial Fibrillation
title_full	The Next 10 Years in Atrial Fibrillation
title_fullStr	The Next 10 Years in Atrial Fibrillation
title_full_unstemmed	The Next 10 Years in Atrial Fibrillation
title_sort	next 10 years in atrial fibrillation
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/55fab9d19d034ce39a86a21f63a95b72
work_keys_str_mv	AT jeffreylturner thenext10yearsinatrialfibrillation AT nassirmarrouche thenext10yearsinatrialfibrillation AT jeffreylturner next10yearsinatrialfibrillation AT nassirmarrouche next10yearsinatrialfibrillation
_version_	1718372794931085312

The Next 10 Years in Atrial Fibrillation

Ejemplares similares